Skip to main content
. 2006 Feb 7;107(11):4250–4256. doi: 10.1182/blood-2005-11-4406

Figure 4.

Figure 4.

Molecular response level versus imatinib mesylate treatment time. Shown is the cumulative percentage of patients achieving either a major molecular response (MMR; BCR-ABL mRNA log-drop ≥ 3) or a complete molecular response (CMR; undetected BCR-ABL mRNA).